Exicure Inc
2H0
Company Profile
Business description
Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.
Contact
400 Seaport Court
Suite 102
Redwood CityCA94063
USAT: +1 847 673-1700
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
8
Stocks News & Analysis
stocks
Our view after Coles’ shares plunge
Shares dropped 8% after reporting results for the September 2026 quarter.
stocks
Cheap ASX share remains overlooked by the market
Fear outweighs fundamentals as ASX share reaffirms outlook.
stocks
Microsoft earnings: Azure accelerates, but investment returns remain the test
We now forecast mildly better revenue growth and EPS growth, alongside more intense near-term cash flow pressure.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,977.20 | 48.20 | -0.53% |
| CAC 40 | 8,028.80 | 59.38 | 0.75% |
| DAX 40 | 25,932.09 | 113.88 | 0.44% |
| Dow JONES (US) | 52,291.03 | 520.72 | 1.01% |
| FTSE 100 | 10,743.04 | 13.26 | 0.12% |
| HKSE | 23,393.32 | 98.90 | 0.42% |
| NASDAQ | 25,640.65 | 203.65 | 0.80% |
| Nikkei 225 | 63,081.86 | 208.25 | -0.33% |
| NZX 50 Index | 13,698.63 | 98.37 | -0.71% |
| S&P 500 | 7,624.74 | 44.67 | 0.59% |
| S&P/ASX 200 | 8,856.50 | 51.60 | -0.58% |
| SSE Composite Index | 3,638.03 | 39.01 | 1.08% |